BR9610058A - Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células - Google Patents

Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células

Info

Publication number: BR9610058A
Authority: BR; Brazil
Prior art keywords: transport; cell; population; protein; peptide
Prior art date: 1995-07-28

Application number

BR9610058A

Other languages

English (en)

Inventor

Peter Francis Joseph O'hare

Gillian Daphne Elliot

Original Assignee

Marie Curie Cancer Care

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-28

Filing date

1996-07-25

Publication date

1999-07-27

1995-07-28 Priority claimed from GBGB9515568.5A external-priority patent/GB9515568D0/en

1996-01-26 Priority claimed from GBGB9601570.6A external-priority patent/GB9601570D0/en

1996-07-25 Application filed by Marie Curie Cancer Care filed Critical Marie Curie Cancer Care

1999-07-27 Publication of BR9610058A publication Critical patent/BR9610058A/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Investigating Or Analysing Biological Materials (AREA)

BR9610058A 1995-07-28 1996-07-25 Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células BR9610058A (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9515568.5A GB9515568D0 (en)	1995-07-28	1995-07-28	Transport proteins and their uses
GBGB9601570.6A GB9601570D0 (en)	1996-01-26	1996-01-26	Transport proteins and their uses
PCT/GB1996/001831 WO1997005265A1 (en)	1995-07-28	1996-07-25	Transport proteins and their uses

Publications (1)

Publication Number	Publication Date
BR9610058A true BR9610058A (pt)	1999-07-27

Family

ID=26307479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9610058A BR9610058A (pt)	1995-07-28	1996-07-25	Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células

Country Status (11)

Country	Link
US (4)	US6184038B1 (pt)
EP (1)	EP0845043B1 (pt)
JP (1)	JPH11510386A (pt)
CN (1)	CN1208438A (pt)
AT (1)	ATE365808T1 (pt)
AU (1)	AU705563B2 (pt)
BR (1)	BR9610058A (pt)
CA (1)	CA2227786A1 (pt)
DE (1)	DE69637147T2 (pt)
MX (1)	MX9800719A (pt)
WO (1)	WO1997005265A1 (pt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997005265A1 (en) *	1995-07-28	1997-02-13	Marie Curie Cancer Care	Transport proteins and their uses
US6017735A (en) *	1997-01-23	2000-01-25	Marie Curie Cancer Care	Materials and methods for intracellular transport and their uses
GB9705903D0 (en) *	1997-03-21	1997-05-07	Elliott Gillian D	VP22 Proteins and uses thereof
JP2002503251A (ja) *	1997-06-02	2002-01-29	カイロンコーポレイション	単純ヘルペスウイルスｖｐ２２ワクチンおよび使用の方法
DE69940805D1 (de)	1998-01-31	2009-06-10	Sinai School Medicine	Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
GB9816761D0 (en) *	1998-07-31	1998-09-30	Phogen Limited	Herpesvirus preparations and their uses
IL141044A0 (en)	1998-08-07	2002-02-10	Univ Washington	Innunological herpes simplex virus antigens and methods for use thereof
DE19845420C2 (de) *	1998-10-02	2000-11-16	Deutsches Krebsforsch	Interzelluläre Ausbreitung rekombinanter DNA
DK1129064T3 (da)	1998-11-12	2008-04-28	Invitrogen Corp	Transfektionsreagenser
US6316252B1 (en) *	1998-12-17	2001-11-13	Wisconsin Alumni Research Foundation	Biotherapeutic delivery system
WO2000053722A2 (en) *	1999-03-10	2000-09-14	Phogen Limited	Delivery of nucleic acids and proteins to cells
JP2002539839A (ja) *	1999-03-31	2002-11-26	インヴィトロゲン・コーポレーション	転位ポリペプチドによる機能性タンパク質配列の送達
US6773920B1 (en)	1999-03-31	2004-08-10	Invitrogen Corporation	Delivery of functional protein sequences by translocating polypeptides
US6451601B1 (en)	1999-04-12	2002-09-17	Modex Therapeutiques, S.A.	Transiently immortalized cells for use in gene therapy
US6358739B1 (en) *	1999-04-12	2002-03-19	Modex Therapeutiques, S.A.	Transiently immortalized cells
AU4342900A (en) *	1999-04-12	2000-11-14	Modex Therapeutiques, S.A.	Transiently immortalized cells for use in gene therapy
DE19933089A1 (de) *	1999-07-15	2001-01-18	Max Delbrueck Centrum	Mittel zur Gewerbsregeneration
AU7473500A (en)	1999-09-01	2001-03-26	University Of Pittsburgh	Identification of peptides that facilitate uptake and cytoplasmic and/or nucleartransport of proteins, dna and viruses
US20030219826A1 (en) *	1999-09-01	2003-11-27	Robbins Paul D.	Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US20030104622A1 (en) *	1999-09-01	2003-06-05	Robbins Paul D.	Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
JP2003512305A (ja)	1999-09-30	2003-04-02	ユニバーシティオブワシントン	免疫学的に重要な単純疱疹ウイルス抗原
US20030108539A1 (en)	2000-02-14	2003-06-12	Christophe Bonny	Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en)	1999-10-12	2004-04-29	Christophe Bonny	Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en)	1999-10-12	2012-05-22	Xigen S.A.	Cell-permeable peptide inhibitors of the JNK signal transduction pathway
DE19955576B4 (de) *	1999-11-18	2008-02-28	Faustus Forschungs Cie. Translational Cancer Research Gmbh	Transferverbindungen, ihre Herstellung und ihre Verwendung
GB9930519D0 (en)	1999-12-24	2000-02-16	Phogen Limited	Uses of transport proteins
DE10001230A1 (de) *	2000-01-13	2001-08-02	Deutsches Krebsforsch	Immunisierungsmittel
US6688084B2 (en) *	2000-03-24	2004-02-10	International Paper Company	Automated bulk box strapper
US7318928B2 (en) *	2000-08-01	2008-01-15	The Johns Hopkins University	Molecular vaccine linking intercellular spreading protein to an antigen
GB0022101D0 (en) *	2000-09-08	2000-10-25	Phogen Ltd	Delivery of substances to cells
US6472176B2 (en) *	2000-12-14	2002-10-29	Genvec, Inc.	Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0112818D0 (en) *	2001-05-25	2001-07-18	Lorantis Ltd	Conjugate
CA2454750C (en)	2001-07-31	2012-09-18	David M. Koelle	Immunologically significant herpes simplex virus antigens and methods for using same
WO2003042239A1 (en) *	2001-11-12	2003-05-22	Stichting Sanquin Bloedvoorziening	Peptides inhibiting signaling by ras-like gtpases
US20060008843A1 (en) *	2002-05-17	2006-01-12	Automated Cell, Inc	Determination of protein function
AU2003254089A1 (en) *	2002-07-19	2004-02-09	Myriad Genetics, Inc	Method and composition for treating and preventing herpesvirus infection
US20040171809A1 (en)	2002-09-09	2004-09-02	Korsmeyer Stanley J.	BH3 peptides and method of use thereof
JP2006517790A (ja) *	2003-01-09	2006-08-03	インヴィトロジェンコーポレーション	ポリペプチド−核酸複合体の細胞の送達および活性化
IL157787A (en) *	2003-09-07	2010-12-30	Mosaid Technologies Inc	Modular outlet for data communications network
ITRM20030376A1 (it)	2003-07-31	2005-02-01	Univ Roma	Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
GB0321311D0 (en) *	2003-09-12	2003-10-15	Phogen Ltd	Delivery of substances to cells
US11660317B2 (en)	2004-11-08	2023-05-30	The Johns Hopkins University	Compositions comprising cardiosphere-derived cells for use in cell therapy
ATE483158T1 (de)	2005-04-05	2010-10-15	Allergan Inc	Clostridientoxinaktivitätstests
US8080517B2 (en)	2005-09-12	2011-12-20	Xigen Sa	Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en)	2005-09-12	2007-03-22	Xigen S.A.	Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8278104B2 (en) *	2005-12-13	2012-10-02	Kyoto University	Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
AU2006325975B2 (en)	2005-12-13	2011-12-08	Kyoto University	Nuclear reprogramming factor
US8129187B2 (en)	2005-12-13	2012-03-06	Kyoto University	Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US20090227032A1 (en)	2005-12-13	2009-09-10	Kyoto University	Nuclear reprogramming factor and induced pluripotent stem cells
EP2172210A1 (en)	2005-12-23	2010-04-07	Partnership&Corp. Technology Transfer	Synthetic peptides for use as inhibitors of neurotransmitter secretion
CA2645853A1 (en)	2006-03-31	2007-11-01	Dana-Farber Cancer Institute	Methods of determining cellular chemosensitivity
US9360473B2 (en)	2006-08-16	2016-06-07	Eutropics Pharmaceuticals, Inc.	Assay system to identify therapeutic agents
US9213999B2 (en)	2007-06-15	2015-12-15	Kyoto University	Providing iPSCs to a customer
JP2008307007A (ja) *	2007-06-15	2008-12-25	Bayer Schering Pharma Ag	出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
GB0724253D0 (en) *	2007-12-12	2008-01-30	Fermentas Uab	Transfection reagent
CA2695522C (en) *	2008-05-02	2019-01-15	Kyoto University	Method of nuclear reprogramming
WO2009143865A1 (en)	2008-05-30	2009-12-03	Xigen S.A.	Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en)	2008-05-30	2009-12-03	Xigen S.A.	Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en)	2008-12-22	2010-07-01	Xigen S.A.	Novel transporter constructs and transporter cargo conjugate molecules
US8460674B2 (en)	2009-02-07	2013-06-11	University Of Washington	HSV-1 epitopes and methods for using same
EP2413950A4 (en)	2009-04-03	2013-05-01	Univ Washington	ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF
GB0917792D0 (en) *	2009-10-12	2009-11-25	Fermentas Uab	Delivery agent
US9856456B2 (en)	2009-10-12	2018-01-02	Thermo Fisher Scientific Baltics Uab	Delivery agent
DK3168229T3 (da) *	2010-03-18	2019-09-23	Spiber Tech Ab	Fremstilling af proteiner og polypeptider.
US9845457B2 (en)	2010-04-30	2017-12-19	Cedars-Sinai Medical Center	Maintenance of genomic stability in cultured stem cells
WO2011160653A1 (en)	2010-06-21	2011-12-29	Xigen S.A.	Novel jnk inhibitor molecules
US8785192B2 (en)	2010-07-07	2014-07-22	Cellular Dynamics International, Inc.	Endothelial cell production by programming
DK2902035T3 (en)	2010-10-14	2018-09-24	Xigen Inflammation Ltd	METHODS FOR TREATING MUSCLE DYROPHY
AU2010362444B2 (en)	2010-10-14	2015-08-06	Xigen Inflammation Ltd.	Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2643459B1 (en)	2010-11-24	2017-09-27	Takara Bio USA, Inc.	Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same
EP2673358B1 (en)	2011-02-08	2019-01-09	FUJIFILM Cellular Dynamics, Inc.	Hematopoietic precursor cell production by programming
SG11201402347YA (en)	2011-11-30	2014-06-27	Xigen Inflammation Ltd	Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome
WO2013091670A1 (en)	2011-12-21	2013-06-27	Xigen S.A.	Novel jnk inhibitor molecules for treatment of various diseases
EP2861238A4 (en)	2012-06-05	2016-03-16	Capricor Inc	OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
US9828603B2 (en)	2012-08-13	2017-11-28	Cedars Sinai Medical Center	Exosomes and micro-ribonucleic acids for tissue regeneration
CA2885230C (en)	2012-09-19	2021-08-03	Anthony Letai	Dynamic bh3 profiling
WO2014206426A1 (en)	2013-06-26	2014-12-31	Xigen Inflammation Ltd.	New use for jnk inhibitor molecules for treatment of various diseases
WO2015197098A1 (en)	2014-06-26	2015-12-30	Xigen Inflammation Ltd.	New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en)	2014-06-26	2015-12-30	Xigen Inflammation Ltd.	New use for jnk inhibitor molecules for treatment of various diseases
AU2014301631A1 (en)	2013-06-26	2015-08-27	Xigen Inflammation Ltd.	New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en)	2013-06-26	2014-12-31	Xigen Inflammation Ltd.	New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
CA2922503C (en)	2013-09-19	2021-10-26	Dana-Farber Cancer Institute, Inc.	Methods of bh3 profiling
US10195280B2 (en)	2014-07-15	2019-02-05	Life Technologies Corporation	Compositions and methods for efficient delivery of molecules to cells
AU2015327812B2 (en)	2014-10-03	2021-04-15	Cedars-Sinai Medical Center	Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3204031A2 (en)	2014-10-08	2017-08-16	Xigen Inflammation Ltd.	New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
RU2717829C2 (ru)	2015-04-20	2020-03-26	Толеро Фармасьютикалз, Инк.	Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
WO2016176288A1 (en)	2015-04-27	2016-11-03	Dana-Farber Cancer Institute, Inc.	High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
ES2739749T3 (es)	2015-05-18	2020-02-03	Tolero Pharmaceuticals Inc	Profármacos de alvocidib que tienen biodisponibilidad aumentada
CN108289861B (zh)	2015-08-03	2021-11-02	大日本住友制药肿瘤公司	用于治疗癌症的组合疗法
WO2017123662A1 (en)	2016-01-11	2017-07-20	Cedars-Sinai Medical Center	Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en)	2016-06-03	2022-06-07	Cedars-Sinai Medical Center	CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en)	2016-09-20	2018-03-29	Cedars-Sinai Medical Center	Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018094275A1 (en)	2016-11-18	2018-05-24	Tolero Pharmaceuticals, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018119000A1 (en)	2016-12-19	2018-06-28	Tolero Pharmaceuticals, Inc.	Profiling peptides and methods for sensitivity profiling
AU2018255346B2 (en)	2017-04-19	2024-05-02	Capricor, Inc.	Methods and compositions for treating skeletal muscular dystrophy
WO2019055579A1 (en)	2017-09-12	2019-03-21	Tolero Pharmaceuticals, Inc.	TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
US11660355B2 (en)	2017-12-20	2023-05-30	Cedars-Sinai Medical Center	Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en)	2018-02-05	2019-08-08	Cedars-Sinai Medical Center	Methods for therapeutic use of exosomes and y-rnas
WO2020117988A1 (en)	2018-12-04	2020-06-11	Tolero Pharmaceuticals, Inc.	Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020176689A1 (en)	2019-02-26	2020-09-03	Dana-Farber Cancer Institute, Inc.	Live cell imaging dynamic bh3 profiling
WO2020191326A1 (en)	2019-03-20	2020-09-24	Sumitomo Dainippon Pharma Oncology, Inc.	Treatment of acute myeloid leukemia (aml) with venetoclax failure
EP4281034A1 (en)	2021-01-24	2023-11-29	Forrest, Michael, David	Inhibitors of atp synthase - cosmetic and therapeutic uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO312681B1 (no)	1990-08-24	2002-06-17	Univ California	Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6251395B1 (en) *	1993-12-23	2001-06-26	W. Michael Gallatin	Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
FR2736915B1 (fr)	1995-07-19	1997-08-22	Rhone Poulenc Rorer Sa	Variants de la proteine p53 et utilisations therapeutiques
WO1997005265A1 (en) *	1995-07-28	1997-02-13	Marie Curie Cancer Care	Transport proteins and their uses
US6017735A (en) *	1997-01-23	2000-01-25	Marie Curie Cancer Care	Materials and methods for intracellular transport and their uses

1996
- 1996-07-25 WO PCT/GB1996/001831 patent/WO1997005265A1/en not_active Ceased
- 1996-07-25 JP JP9507359A patent/JPH11510386A/ja not_active Ceased
- 1996-07-25 US US09/011,073 patent/US6184038B1/en not_active Expired - Fee Related
- 1996-07-25 CA CA002227786A patent/CA2227786A1/en not_active Abandoned
- 1996-07-25 EP EP96925874A patent/EP0845043B1/en not_active Expired - Lifetime
- 1996-07-25 BR BR9610058A patent/BR9610058A/pt not_active Application Discontinuation
- 1996-07-25 AU AU66239/96A patent/AU705563B2/en not_active Ceased
- 1996-07-25 AT AT96925874T patent/ATE365808T1/de not_active IP Right Cessation
- 1996-07-25 DE DE69637147T patent/DE69637147T2/de not_active Expired - Fee Related
- 1996-07-25 CN CN96195845A patent/CN1208438A/zh active Pending
1998
- 1998-01-26 MX MX9800719A patent/MX9800719A/es unknown
2001
- 2001-01-31 US US09/773,430 patent/US6521455B2/en not_active Expired - Fee Related
2002
- 2002-09-27 US US10/259,198 patent/US20030219859A1/en not_active Abandoned
2005
- 2005-03-08 US US11/075,628 patent/US20060051869A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE365808T1 (de)	2007-07-15
CA2227786A1 (en)	1997-02-13
DE69637147D1 (de)	2007-08-09
EP0845043B1 (en)	2007-06-27
MX9800719A (es)	1998-11-29
DE69637147T2 (de)	2008-03-06
WO1997005265A1 (en)	1997-02-13
JPH11510386A (ja)	1999-09-14
AU705563B2 (en)	1999-05-27
AU6623996A (en)	1997-02-26
CN1208438A (zh)	1999-02-17
US20030219859A1 (en)	2003-11-27
US6521455B2 (en)	2003-02-18
US20020039765A1 (en)	2002-04-04
EP0845043A1 (en)	1998-06-03
US6184038B1 (en)	2001-02-06
US20060051869A1 (en)	2006-03-09

Publication	Publication Date	Title
BR9610058A (pt)	1999-07-27	Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células
Murray et al.	1982	Nucleotide sequences of transcription and translation initiation regions in Bacillus phage phi 29 early genes.
Köhrer et al.	2001	Import of amber and ochre suppressor tRNAs into mammalian cells: a general approach to site-specific insertion of amino acid analogues into proteins
BR9610511B1 (pt)	2010-10-19	construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
Ciechanover et al.	1985	Transfer RNA is an essential component of the ubiquitin-and ATP-dependent proteolytic system.
BRPI9811940A (pt)	2000-09-05	vetor de expressão para um polipeptídeo de ligação da interleucina-18 (il-18-bp), célula hospedeira procariótica transformada com o referido vetor, processo para produção de il-18-bp, proteína de fusão compreendendo o referido polipeptídeo, bem como il-18bp modificada.
BR9803346B1 (pt)	2013-11-12	Cepa de microorganismos transformados, bem como processo para a preparação fermentativa de l-cisteína, l-cistina, n-acetil-serina ou derivados de tiazolidina
ATE352638T1 (de)	2007-02-15	REVERSE ßTWO-HYBRIDß-SYSTEME
DE69943068D1 (de)	2011-02-03	Transfer von mRNA unter Verwendung von polykationischen Verbindungen
BR9712942A (pt)	2000-04-04	Método para a produção de glicerol, célula hospedeira transformada, método para a seleção da expressão do gene, cepa pah21/dh5x de escherichia coli e cepa pah21/dh5x de escherichia coli.
HUP9700428A2 (hu)	1998-06-29	Célsejtspecifikus vektorok gének beépítésére, a vektorokat tartalmazó gyógyászati készítmények és azok alkalmazása
Meng	1982	PURIFICATION, CHARACTERIZATION AND AMINO ACID SEQUENCE OF THIOREDOXIN FROM CORYNEBACTERIUM NEPHRIDII.
BR9806866A (pt)	2000-04-18	Cassete de expressão e uso do mesmo, cepa do cassete de expressão, vetor de ácido nucleico, cepa viral, composição farmacêutica, e, processos para estudar a função de um ou mais genes heterólogos em uma célula eucariótica, para produzir uma cepa de hsv, para tratamento do corpo humano ou animal e para realizar terapia genética em um humano ou animal, e, vacina.
BR9811865A (pt)	2000-08-15	Isolamento de um novo gene de fator de senescência, p23
HUP9900750A2 (hu)	1999-06-28	Gén kifejezésére szolgáló promóterek
IL145866A0 (en)	2002-07-25	Nucleic acid sequences encoding an organic anion transport protein
Pan et al.	1993	Identification of the functional domains of the FLP recombinase. Separation of the nonspecific and specific DNA-binding, cleavage, and ligation domains.
Schray et al.	1991	Binding of human glutaminyl-tRNA synthetase to a specific site of its mRNA
DE59712771D1 (de)	2007-01-11	Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
Haining et al.	1990	A critical arginine in the large subunit of ribulose bisphosphate carboxylase/oxygenase identified by site-directed mutagenesis.
Etherington et al.	1969	Investigation of the cathepsins of human gastric carcinomata
BR9909044A (pt)	2000-12-05	Vetor de tranferência de ácidos nucleicos, composição, utilização de um vetor de tranferência de ácidos nucleicos, processos de transfecção de ácidos nucleicos nas células, e de tratamento de doenças, e, célula recombinante
Geetha et al.	1980	An in vitro protein-synthesizing system with isolated chloroplasts of Sorghum vulgare. An alternate assay system for exogenous template RNA.
ATE302282T1 (de)	2005-09-15	Erhöhte herstellung von sekretierten proteinen durch rekombinante hefezellen
BR9507507A (pt)	1997-09-02	Polipeptideo proteina para uso como uma toxina sequéncia de nucleotídeos processo para produzir um polipeptideo molécula de dna recombinante vetor de express o célula inseticida sistema inseticida planta animal n o humano toxina processo para produzir um polipeptídeo ativo de um polipeptídeo precursor inativo isolado sequéncia base de nucleotídeos isolada sequéncia base siolada nova toxina poliptídeo isolado e novo assunto ou combinaç o

Legal Events

Date	Code	Title	Description
2003-01-07	EG	Technical examination (opinion): publication of technical examination (opinion)
2003-10-14	FB36	Technical and formal requirements: requirement - article 36 of industrial property law
2005-10-25	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2008-06-03	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, COM BASE NOS ART. 10 (VIII) E ART. 25 DA LPI VIGENTE.